ClinicalTrials.gg
TerminatedNCT01374451COOPERATE-2Updated Dec 20, 2016Results posted

Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

A Phase 2 interventional study of Everolimus and Pasireotide LAR in Islet Cell Tumor, sponsored by Novartis Pharmaceuticals. Terminated at 47 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-20.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was stopped for not meeting the primary endpoint for PFS.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will estimate the treatment effect of everolimus in combination with pasireotide LAR relative to everolimus alone on progression-free survival (PFS) in patients with advanced progressive PNET.

A planned primary analysis was completed with data cut of 02-Apr-2014. The study did not meet its primary objective, which was based on progression-free survival (PFS) as per local radiology assessment and was prematurely terminated with the last patient last visit on 19-Feb-2015. However, it is important to note that the data did not reveal any new safety concerns. It was decided to stop the study and this decision was shared with the study sites on 31-Jul-2014.

02

Conditions studied

  • Islet Cell Tumor

Keywords

  • Pancreatic
  • Neuroendocrine tumors
  • PNET
  • Pasireotide
  • Everolimus
  • Advanced progressive pancreatic neuroendocrine tumor
03

In context

Adenoma, Islet Cell

113 studies on the registry are indexed under Adenoma, Islet Cell; 30 are open to participants now.

This study's enrollment of 160 is above the median of 38 across 76 interventional studies indexed under Adenoma, Islet Cell.

Browse Adenoma, Islet Cell studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced confirmed well differentiated pancreatic neuroendocrine tumor
  • Progressive disease within the last 12 months
  • per Version 1.0 determined by multiphase MRI or triphasic CT

Exclusion criteria

Exclusion Criteria:

  • Patients currently requiring somatostatin analog treatment
  • Prior therapy with mTOR inhibitors or pasireotide
  • Patients with more than 2 prior systemic treatment regimens
  • Previous cytotoxic chemotherapy, targeted therapy, somatostatin analogs, or biotherapy within the last 4 weeks

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Paseriotide LAR + Everolimus

    everolimus 10 mg once daily po in combination with pasireotide LAR 60 mg every 28 days (q28d) im

    Drug: Everolimus · Drug: Pasireotide LAR

  • Experimental
    Everolimus

    everolimus 10 mg once daily po alone

    Drug: Everolimus

Interventions

  • Everolimus was supplied as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets

    Also known as: RAD001

  • Pasireotide LAR intra-muscular depot injections were supplied as a powder in vials containing 20 mg and 40 mg with ampoules containing 2 mL of vehicle (for reconstitution).

    Also known as: SOM230 LAR

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Per Local Radiological Review

    PFS per RECIST 1.0. (Response Evaluation Criteria in Solid Tumors). PFS was defined as the time from the date of randomization to the date of the first radiologically documented disease progression or death due to any cause.

    Time frame: Once 80 PFS events had occurred aproximately after 24 months

Secondary outcomes

  1. Safety and Tolerability Profile of Everolimus Alone or in Combination With Pasireotide LAR

    Consisted of monitoring and recording the rate, type, severity, and causal relationship of adverse events (AEs) and serious AEs (SAEs) to treatment. The safety analysis was based mainly on the frequency of AEs or SAEs and on the number of laboratory values that fell outside of pre-determined range.

    Time frame: Once 80 PFS events had occurred

  2. Objective Response Rate (ORR) as Per Radiology Review

    Objective response was determined by the local radiologist according to the RECIST Version 1.0. ORR is the percentage of patients with a best overall response of complete response (CR) or partial response (PR). This is also referred to as Overall response rate. CR: Disappearance of all nontarget lesions. PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the smallest sum of the longest diameter of all target lesions recorded at or after baseline.

    Time frame: Once 80 PFS events had occurred

  3. Duration of Response (DoR)

    80 PFS are expected after approximately 24 months. Kaplan Meier was initially planned to be used to depict duration of response by treatment group and by stratum. Later based on the mode of action of everolimus and pasireotide and based on study experience, only a low number of objective responses per RECIST were expected. Therefore, protocol was amended to only list duration of response, and confirmed responses were flagged in the listing. Hence, statistical analyses were not planned and such data are not available for the following table.

    Time frame: Once 80 PFS events had occurred

  4. Overall Survival (OS) Using Kaplan Meier Method

    Overall survival was defined as the time from date of randomization/start of treatment to date of death due to any cause. If a patient is not known to have died, survival was to be censored at the date of last contact.

    Time frame: Once 80 PFS events had occurred

  5. PFS and the Predictive Probability of Success in Phase III

    105 PFS events expected after approximately 36 months

    Time frame: Once 105 PFS events had occurred occurred

  6. Disease Control Rate (DCR) as Per Radiology Review

    Disease control rate is the percentage of patients with a best overall response of CR or PR or stable disease (SD) determined by the local radiologist according to the Response Evaluation Criteria In Solid Tumors Criteria (RECIST) Version 1.0. CR: Disappearance of all nontarget lesions. PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the smallest sum of the longest diameter of all target lesions recorded at or after baseline. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease (PD). PD: Any progression ≤ 18 weeks after randomization (and not qualifying for CR, PR or stable disease SD.

    Time frame: Once 80 PFS events had occurred

  7. Summary of Pharmacokinetics (PK) for Everolimus for AUClast

    Time frame: Cycle 2 Day 1

  8. Summary of Pharmacokinetics (PK) for Everolimus for CL/F

    Time frame: Cycle 2 Day 1

  9. Summary of Pharmacokinetics (PK) for Everolimus for Cmax and Cmin

    Time frame: Cycle 2 Day 1

  10. Summary of Pharmacokinetics (PK) for Everolimus for Tmax

    Time frame: Cycle 2 Day 1

  11. Summary of Pasireotide Concentrations Following Intramuscular Injection of Pasireotide LAR 60mg

    Time frame: Cycle 1 Day 21, Cycle 2 Day 29

07

Results

Posted Dec 20, 2016
Limitations and caveats
A planned primary analysis was completed with data cut of 02-Apr-2014. The study did not meet its primary objective, which was based on progression-free survival as per local radiology assessment and was prematurely terminated.

Participant flow

Participant flow — Overall Study
MilestonePaseriotide LAR + EverolimusEverolimus
Started7981
Completed7881
Not completed10
Withdrew: Administrative problems10

Outcome measures

PrimaryProgression-free Survival (PFS) Per Local Radiological Review

PFS per RECIST 1.0. (Response Evaluation Criteria in Solid Tumors). PFS was defined as the time from the date of randomization to the date of the first radiologically documented disease progression or death due to any cause.

Time frame:
Once 80 PFS events had occurred aproximately after 24 months
Reported as:
Median · months
Progression-free Survival (PFS) Per Local Radiological Review
monthsPaseriotide LAR + EverolimusEverolimus
Progression-free Survival (PFS) Per Local Radiological Review16.82 (12.09 to 19.58)16.59 (11.07 to 19.48)
Statistical analysis
  • Paseriotide LAR + Everolimus vs Everolimus · Log Rank · p = 0.488 · Hazard ratio (hr): 0.991 · 95% CI 0.636 to 1.543
SecondarySafety and Tolerability Profile of Everolimus Alone or in Combination With Pasireotide LAR

Consisted of monitoring and recording the rate, type, severity, and causal relationship of adverse events (AEs) and serious AEs (SAEs) to treatment. The safety analysis was based mainly on the frequency of AEs or SAEs and on the number of laboratory values that fell outside of pre-determined range.

Time frame:
Once 80 PFS events had occurred
Reported as:
Number · Participants
Safety and Tolerability Profile of Everolimus Alone or in Combination With Pasireotide LAR
ParticipantsPaseriotide LAR + EverolimusEverolimus
Deaths710
Serious Adverse Events4149
Adverse Events7881
SecondaryObjective Response Rate (ORR) as Per Radiology Review

Objective response was determined by the local radiologist according to the RECIST Version 1.0. ORR is the percentage of patients with a best overall response of complete response (CR) or partial response (PR). This is also referred to as Overall response rate. CR: Disappearance of all nontarget lesions. PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the smallest sum of the longest diameter of all target lesions recorded at or after baseline.

Time frame:
Once 80 PFS events had occurred
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) as Per Radiology Review
Percentage of participantsPaseriotide LAR + EverolimusEverolimus
Objective Response Rate (ORR) as Per Radiology Review20.3 (12.0 to 30.8)6.2 (2.0 to 13.8)
SecondaryDuration of Response (DoR)

80 PFS are expected after approximately 24 months. Kaplan Meier was initially planned to be used to depict duration of response by treatment group and by stratum. Later based on the mode of action of everolimus and pasireotide and based on study experience, only a low number of objective responses per RECIST were expected. Therefore, protocol was amended to only list duration of response, and confirmed responses were flagged in the listing. Hence, statistical analyses were not planned and such data are not available for the following table.

Time frame:
Once 80 PFS events had occurred

No measurements were reported for this outcome.

SecondaryOverall Survival (OS) Using Kaplan Meier Method

Overall survival was defined as the time from date of randomization/start of treatment to date of death due to any cause. If a patient is not known to have died, survival was to be censored at the date of last contact.

Time frame:
Once 80 PFS events had occurred
Reported as:
Number · Percentage of participants
Overall Survival (OS) Using Kaplan Meier Method
Percentage of participantsPaseriotide LAR + EverolimusEverolimus
6 months93.5 (85.0 to 97.2)93.7 (85.5 to 97.3)
12 months85.5 (75.4 to 91.7)86.1 (76.2 to 92.0)
18 months81.4 (70.6 to 88.5)75.5 (64.3 to 83.6)
24 months77.0 (65.6 to 85.1)71.0 (59.3 to 79.9)
SecondaryPFS and the Predictive Probability of Success in Phase III

105 PFS events expected after approximately 36 months

Time frame:
Once 105 PFS events had occurred occurred

No measurements were reported for this outcome.

SecondaryDisease Control Rate (DCR) as Per Radiology Review

Disease control rate is the percentage of patients with a best overall response of CR or PR or stable disease (SD) determined by the local radiologist according to the Response Evaluation Criteria In Solid Tumors Criteria (RECIST) Version 1.0. CR: Disappearance of all nontarget lesions. PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the smallest sum of the longest diameter of all target lesions recorded at or after baseline. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease (PD). PD: Any progression ≤ 18 weeks after randomization (and not qualifying for CR, PR or stable disease SD.

Time frame:
Once 80 PFS events had occurred
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR) as Per Radiology Review
Percentage of participantsPaseriotide LAR + EverolimusEverolimus
Disease Control Rate (DCR) as Per Radiology Review77.2 (66.4 to 85.9)82.7 (72.7 to 90.2)
SecondarySummary of Pharmacokinetics (PK) for Everolimus for AUClast
Time frame:
Cycle 2 Day 1
Reported as:
Mean · ng*hr/mL
Summary of Pharmacokinetics (PK) for Everolimus for AUClast
ng*hr/mLPaseriotide LAR + EverolimusEverolimus
Summary of Pharmacokinetics (PK) for Everolimus for AUClast511 ± 91.8378 ± 123
SecondarySummary of Pharmacokinetics (PK) for Everolimus for CL/F
Time frame:
Cycle 2 Day 1
Reported as:
Mean · L/hr
Summary of Pharmacokinetics (PK) for Everolimus for CL/F
L/hrPaseriotide LAR + EverolimusEverolimus
Summary of Pharmacokinetics (PK) for Everolimus for CL/F20.0 ± 3.2129.0 ± 9.51
SecondarySummary of Pharmacokinetics (PK) for Everolimus for Cmax and Cmin
Time frame:
Cycle 2 Day 1
Reported as:
Mean · ng/mL
Summary of Pharmacokinetics (PK) for Everolimus for Cmax and Cmin
ng/mLPaseriotide LAR + EverolimusEverolimus
Cmax58.7 ± 25.960.2 ± 30.6
Cmin14.7 ± 4.817.67 ± 4.41
SecondarySummary of Pharmacokinetics (PK) for Everolimus for Tmax
Time frame:
Cycle 2 Day 1
Reported as:
Median · hr
Summary of Pharmacokinetics (PK) for Everolimus for Tmax
hrPaseriotide LAR + EverolimusEverolimus
Summary of Pharmacokinetics (PK) for Everolimus for Tmax1.00 ± 4.810.500 ± 4.41
SecondarySummary of Pasireotide Concentrations Following Intramuscular Injection of Pasireotide LAR 60mg
Time frame:
Cycle 1 Day 21, Cycle 2 Day 29
Reported as:
Mean · ng/mL
Summary of Pasireotide Concentrations Following Intramuscular Injection of Pasireotide LAR 60mg
ng/mLPaseriotide LAR + Everolimus
Cycle 1 Day 21 (n:69)21.6 ± 13.1
Cycle 2 Day 29 (n: 64)19.9 ± 12.1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus LAR + Pasireotide—41/78 (52.6%)77/78 (98.7%)
Everolimus—49/81 (60.5%)80/81 (98.8%)
Most frequent serious events
Showing 10 of 136
Most frequent serious events
EventEverolimus LAR + PasireotideEverolimus
PyrexiaGeneral disorders5/786/81
HyperglycaemiaMetabolism and nutrition disorders5/781/81
AnaemiaBlood and lymphatic system disorders0/785/81
Abdominal painGastrointestinal disorders1/785/81
SepsisInfections and infestations2/784/81
NauseaGastrointestinal disorders1/783/81
VomitingGastrointestinal disorders2/783/81
CholangitisHepatobiliary disorders2/783/81
Renal failureRenal and urinary disorders1/783/81
DyspnoeaRespiratory, thoracic and mediastinal disorders0/783/81
Most frequent other events
Showing 10 of 80
Most frequent other events
EventEverolimus LAR + PasireotideEverolimus
HyperglycaemiaMetabolism and nutrition disorders56/7823/81
StomatitisGastrointestinal disorders46/7851/81
DiarrhoeaGastrointestinal disorders49/7843/81
Oedema peripheralGeneral disorders26/7831/81
Abdominal painGastrointestinal disorders22/7829/81
NauseaGastrointestinal disorders27/7824/81
CoughRespiratory, thoracic and mediastinal disorders21/7828/81
FatigueGeneral disorders21/7827/81
HeadacheNervous system disorders17/7826/81
Weight decreasedInvestigations24/7825/81

Baseline characteristics

Full analysis set (FAS) was defined according to the intention to treat principle. The FAS consisted of all randomized patients. Following the intention to treat principle patients were analyzed according to the treatment (and stratum) they were assigned to at randomization.

Age, Continuous
Age, Continuous(Years)Paseriotide LAR + EverolimusEverolimusTotal
Mean56.52 ± 11.97858.22 ± 12.65057.38 ± 12.314
Gender
Gender(Participants)Paseriotide LAR + EverolimusEverolimusTotal
Female403474
Male394786
08

Study locations

47 sites
  • Dana Farber Cancer Institute SC-2
    Boston, Massachusetts 02115, United States
  • Montefiore Medical Center MMC
    Bronx, New York 10467, United States
  • Oregon Health & Science University Knight Cancer Institute
    Portland, Oregon 97239, United States
  • University of Texas/MD Anderson Cancer Center UT MD Anderson Cancer Ctr
    Houston, Texas 77030-4009, United States
  • Novartis Investigative Site
    Caba, Buenos Aires C1426ANZ, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1264AAA, Argentina
  • Novartis Investigative Site
    St. Leonards, New South Wales 2065, Australia
  • Novartis Investigative Site
    Herston, Queensland 4029, Australia
  • Novartis Investigative Site
    Bruxelles, 1070, Belgium
  • Novartis Investigative Site
    Bruxelles, 1200, Belgium
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Haine-saint-Paul, 7100, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Rio de Janeiro, RJ 20230-130, Brazil
  • Novartis Investigative Site
    São Paulo, SP 01246-000, Brazil
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Montreal, Quebec H1T 2M4, Canada
  • Novartis Investigative Site
    Copenhagen N, DK-2200, Denmark
  • Novartis Investigative Site
    Århus, 8000, Denmark
  • Novartis Investigative Site
    Bordeaux Cedex, 33075, France
  • Novartis Investigative Site
    Clichy, 92110, France
  • Novartis Investigative Site
    Lyon, 69437, France
  • Novartis Investigative Site
    Marseille cedex 05, 13385, France
  • Novartis Investigative Site
    Villejuif Cedex, 94805, France
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    München, 81675, Germany
  • Novartis Investigative Site
    Budapest, 1062, Hungary
  • Novartis Investigative Site
    Budapest, 1085, Hungary
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Milano, MI 20141, Italy
  • Novartis Investigative Site
    Modena, MO 41100, Italy
  • Novartis Investigative Site
    Fukuoka-city, Fukuoka 812-8582, Japan
  • Novartis Investigative Site
    Rotterdam, 3015 CE, Netherlands
  • Novartis Investigative Site
    Grafton, Auckland, New Zealand
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Hospitalet de LLobregat, Catalunya 08907, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Lund, SE-221 85, Sweden
  • Novartis Investigative Site
    Uppsala, SE-751 85, Sweden
  • Novartis Investigative Site
    Bangkok, 10330, Thailand
  • Novartis Investigative Site
    Bangkok, 10700, Thailand
  • Novartis Investigative Site
    Ankara, 06100, Turkey
  • Novartis Investigative Site
    Istanbul, 34303, Turkey
  • Novartis Investigative Site
    Cambridge, CB2 2QQ, United Kingdom
  • Novartis Investigative Site
    Glasgow, G12 0YN, United Kingdom
  • Novartis Investigative Site
    Manchester, M20 9BX, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2011
First posted
Jun 16, 2011
Start
Jun 2011
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Results first posted
Dec 20, 2016
Last update
Dec 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01374451
Responsible party
Sponsor
First posted
Jun 16, 2011
Start date
Jun 2011
Primary completion
Feb 2015
Completion
Feb 2015
Results posted
Dec 20, 2016
Last update
Dec 20, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion